ArticleScientific reports2025
MiRNome alterations drive the malignant transformation of endometriosis into endometriosis-correlated ovarian cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Novel Exploratory Transcriptomic Candidates as Biomarkers and Cancer Hallmark Fingerprints for Ovarian Endometroid and Clear Cell Carcinomas in Women.Antioxidants (Basel, Switzerland) · 2026Article
- Review
- tsRNA-Ala-3-0030 drives ovarian cancer progression by suppressing ZNF70.Frontiers in oncology · 2026Article
- Borderline ovarian clear cell tumor arising from endometriosis during long-term dienogest therapy: a case report.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis (EMS) is a chronic gynecological condition affecting 6-10% of reproductive-age women. These lesions, albeit of benign nature, present cancer-like features, and may progress to epithelial ovarian cancer (EOC) through a multistep process. The coexistence of EMS and EOC in the presence of transitional lesions (TL) - i.e. atypical EMS/borderline lesions - is termed as endometriosis-correlated ovarian cancer (ECOC). Given the regulatory role of miRNAs in gene expression and biological pathways, we aimed to identify miRNAs that may drive or modulate the malignant transformation of ovarian EMS. Global miRNA profiling was evaluated on 81 samples (EMS, TL and ECOC) from 44 patients. Principal component analysis and unsupervised clustering revealed two distinct clusters formed by ECOC and ovarian EMS samples, whereas TL were dispersed among the other two. Differential expression analysis (DEA) of TL vs. ovarian EMS, revealed 30 significantly upregulated miRNAs. Comparison of ECOC vs. TL samples yielded 118 significantly upregulated and 77 downregulated miRNAs. Finally, DEA of ECOC vs. ovarian EMS lesions yielded 200 upregulated and 128 downregulated miRNAs. Evaluation of miRNAs commonly deregulated between the three groups showed 14 shared upregulated miRNAs (miR-429, miR-425-5p, miR-200c-3p, miR-200c-5p, miR-200b-3p, miR-200a-3p, miR-183-5p, miR-182-5p, miR-141-5p, miR-141-3p, miR-96-5p, miR-93-5p, miR-10a-5p, miR-10a-3p) with a progressive increase in expression levels, from ovarian EMS to TL and ultimately to ECOC. The identified miRNA expression profiles associated with the progression from ovarian EMS, TL and ECOC provide valuable insights into the molecular progression from benign to malignant lesions and could represent potential biomarkers for the early detection of ECOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.